CORPORATE GOVERNANCE

IPO OFFER SUMMARY

Size of the issue: The Company is offering a minimum of 1,581,722 and a maximum of 2,636,204 Units consisting of an equal number of Offer Shares and IPO Warrants, corresponding to gross proceeds between DKK 9.0 to 15 million from the Offering.
Price pr. unit: DKK 5,69 (consisting of one Offer Share and one IPO Warrant)
Valuation (pre-money): DKK 40 million
Subscription period: 17-30 September, 2021
Preliminary first day of trading: 7 October, 2021
Minimum subscription: 700 units
Listing on Nasdaq First North GM: Prior to the Offering, the Shares have not been publicly traded. The Company has applied for admission to trading of all Shares and the IPO Warrants on Nasdaq First North Growth Market Denmark (“First North Growth Market”) under the ticker “BRAINP”. First day of trading of the Shares (Permanent ISIN: DK0061670205) and the IPO Warrants (ISIN: DK0061670551) is expected to be on 7 October, 2021. All Shares will have the same rights and will rank pari passu in every respect.

EXECUTIVE TEAM

KIM BADEN-KRISTENSEN

Co-founder & CEO
Shares before the IPO: 2 533 500

Former Vice President of Marketing & Strategy @ world’s largest wind energy co. 5 years @ Boston Consulting Group. M.Sc. Management of Technology, CBS Cognitive Psychology studies, UCPH. Healthcare Innovation degree HARVARD Business School (Pasteur Program).

ULRIK DITLEV ERIKSEN

Co-founder & CPO
Shares before the IPO: 1 569 055

20 years of experience with strategic build-up of high-tech companies within biotech, MedTech, energy, ICT and engineering. M.Sc. International Business, CBS. Cognitive Psychology studies, UCPH Executive Innovation Leadership, INSEAD.

BETH WOLFF

Chief Commercial Officer
Shares before the IPO: 170 152

15 years of experience leading teams in commercial excellence at Novo Nordisk, LEO Pharma and Sandoz. Commercial Lead for the EU launch of the first in-licensed digital therapeutic at Sandoz.
MA Political Economy, M.Sc. Public Health

SIMON NIELSEN

Director of Research & Innovation

Director of Research & Innovation
12 years of experience as a biomedical engineer.
Experience from several medtech startups
Senior scientist & team mgr. at Coloplast.
Postdoc, Cognitive Neuroscience, University of Copenhagen.
PhD. Cognition and psychophysics, DTU.

BRIAN ØSTERGAARD

Business Development Manager

Entrepreneur in public health care and digital health with successful exit of his company in Autism & dementia care software.
25 years experience in selling into public and private health care sectors.

HELLE BEHRNDTZ JENSEN

Finance Manager

Many years of financial management experience from the insurance and the venture industry. In-depth experience in preparation and execution of business plans and strategic management, and in supporting the business with strong gov- ernance and financial procedures.

PAULA PETCU

Chief Technology Officer

10+ years in Software Development, 7 years in Pharma. Formerly Head of Digital Technologies at Lundbeck. Tech nerd and team manager. One of Berlingske’s Top 100 Talent in Denmark. MSc in Computer Science from University of Copenhagen. Co-founded health tech companies FindZebra and Healthy Mind Tech.

BOARD OF DIRECTORS

LARS TERNEY

Joined as chairman from H1 2021
Independent
Shares before the IPO: 678 306

Senior Partner, Nordic Capital
13 years in Private Equity, 14 years Head of Boston Consulting Group Denmark. Lars is an international heavy weight within business, strategy and economics.

JONAS NILSEN

Board Member since Sep 2018
Independent
Shares before the IPO: 40 000

Digital health and therapuetics entrepreneur, Co-founder & Chief Innovation Officer at Practio, Doctor of Medicine from University of CPH. Innovation Management, Harvard Business School.

KIM ARVID NIELSEN

Board Member since Nov 2019
Independent
Shares before the IPO: 20.000

Experienced Pharma & Biotech CEO Follicum AB (former inProTher , CytoVac, Scandion Oncology, Serendex Pharmaceuticals) GM, VP & Dir. (Bayer, Basilea Pharmaceutica, Astra Zeneca, Ferrosan). MD, UCPH, MBA, SIMI.

HANNE LETH HILLMAN

Board Member since May 2021
Independent

Experienced life science executive focused on finance, communications and investor relations (IR). Additionally brings strong board experience. Currently the CFO for Nanovi A/S.

ADVISERS

Certified Adviser:
Keswick Global AG
Hoffingergasse 16/1/6
A 1120 Vienna, Austria
Info@keswickglobal.com
+43 1 740 408045
www.keswickglobal.com

Financial adviser:
Gemstone Capital A/S
Strandvejen 60
2900 Hellerup
Info@gemstonecapital.com
+45 33 22 07 00
gemstonecapital.com

Auditor:
Deloitte Statsautoriseret Revisionpartnerselskab
Weiderkampsgade 6
2300 Copenhagen S
mfauerskov@deloitte.dk
deloitte.com/